Jay Flatley On Sequencing, Cancer, and FDA

Aug 19, 2010

The San Diego Union-Tribune's Keith Darcé recently spoke with Illumina CEO Jay Flatley about the company's share in the sequencing market, its lowered whole-genome sequencing price, its plans to develop diagnostic tests for certain cancers, and its recent involvement with the US Food and Drug Administration's push to regulate DTC genetic testing.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Another Cold Case Arrest

A 50-year-old cold case was cracked using genetic genealogy, the New York Times reports.

Circumventing that Pesky Poison

NPR reports that some insect pests are now becoming resistant to Bt crops.

Not Convened

Science reports the US Food and Drug Administration did not consult an outside panel in its approval of remdesivir as a COVID-19 treatment.

Nature Papers Describe Future Path for Human Genomic Research, Method to Analyze RNA Structure With Nanopore Sequencing, More

In Nature this week: a framework for future human genomic research, PORE-cupine approach to study RNA structure using nanopore sequencing, and more.

Menu